Abstract
Cis-Diamminodichloroplatinum (II), or DDP, has been shown to be an effective agent in the treament of various neoplastic diseases. The drug has been usually administered in high intravenous (IV) bolus dose, or rapid infusion. By these schedules, the toxicity of DDP included severe nausea and vomiting, nephrotoxicity, mild to moderate myelosuppression, and hearing loss1. Renal and gastrointestinal toxicities were dose-limiting and constituted major obstacles to prlonged therapy. Although nephrotoxicity was partially ameliorated by fluid and mannitol diuresis2, it remains a major impediment of long-term treatment. Also, in several studies, nausea and vomiting were so severe that many patients refused to continue treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
DeConti RC, Toftness BR, Lange RC, Creasey WA. Clinical and pharmacological studies with cis-dichlorodiammineplastinum (II). Cancer Res1973; 33: 1310 - 1315.
Hayes D, Cvitkovic E, Golbey R, Schneider E, Krakoff IH. Amelioration of renal toxicity of high-dose cis-platinum-diamminedichloride (CPDD) by mannitol-induced diuresis. (Abstr) Proc Am Assoc Cancer Res1976; 17: 169.
Salem PA, Hall SW, Benjamin RS, Murphy WK, Wharton JT, Bodey GP. Clinical phase I-II study of cis-dichlorodiammineplatinum (II) given by continuous IV infusion. Cancer Treat Rep1978; 62: 1553 - 1555.
Drewinko B, Brown BW, Gottlieb JA. The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res1973; 33: 3091 - 3095.
Sidgestad CP, Grdina DJ, Peters LJ, Stutesman J. Cell cycle phase preferential killing of fibrosarcoma tumor cells by cis-dichloro- diammineplatinum or Adriamycin (Abstr). Proc Am Assoc Cancer Res1979; 20: 178.
Salem PA, Jabboury KW, Khalil MF. Severe nephrotoxicity: A probable complication of cis-dichlorodiammineplatinum (II) and cephalothin- gentamycin therapy. Oncology1982; 39: 31 - 32.
Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. Acute renal failure after cis-dichlorodiammineplatinum (II) and gentamycin- cephalothin therapies. Cancer Treat Rep1978; 62: 693 - 698.
Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cis-piatin. Ann Intern Med1979; 90: 929 - 931.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Salem, P., Khalyl, M., Jabboury, K., Hashimi, L. (1986). The 5-Day Continuous Infusion of Cis-Platinum: An Update on Toxicity Pattern. In: Rosenthal, C.J., Rotman, M. (eds) Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2197-2_13
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2197-2_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9291-3
Online ISBN: 978-1-4613-2197-2
eBook Packages: Springer Book Archive